CPTS Share Price

Open 31.00 Change Price %
High 31.02 1 Day 0.05 0.16
Low 30.98 1 Week 0.00 0.00
Close 31.02 1 Month 0.00 0.00
Volume 655586 1 Year 0.00 0.00
52 Week High 2.70
52 Week Low 0.00
CPTS Important Levels
Resistance 2 31.06
Resistance 1 31.04
Pivot 31.01
Support 1 31.00
Support 2 30.98
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Conceptus, Inc. (NASDAQ: CPTS)

CPTS Technical Analysis 5
As on 5th Jun 2013 CPTS Share Price closed @ 31.02 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 22.30 & Strong Buy for SHORT-TERM with Stoploss of 27.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
CPTS Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CPTS Other Details
Segment EQ
Market Capital 602187392.00
Sector Health Care Medical/Dental Instruments
Industry
Offical website
CPTS Address
CPTS
N/A
CPTS Latest News
Interactive Technical Analysis Chart Conceptus, Inc. ( CPTS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Conceptus, Inc.
CPTS Business Profile
Conceptus, Inc. designs, develops, markets and promotes solutions in women�s healthcare. The Company�s flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman�s fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.